<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594827</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00017536</org_study_id>
    <nct_id>NCT01594827</nct_id>
  </id_info>
  <brief_title>Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)</brief_title>
  <acronym>PMEP</acronym>
  <official_title>Persistent MRSA Eradication Protocol (PMEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in
      Cystic Fibrosis (CF) has increased dramatically over the last decade. Evidence suggests that
      persistent infection with MRSA may result in an increased rate of decline in Forced
      Expiratory Volume (FEV)1 and shortened survival. Currently there are no conclusive studies
      demonstrating an effective aggressive treatment protocol for persistent MRSA respiratory
      infection in CF. Data demonstrating an effective and safe method of clearing persistent MRSA
      infection are needed.

      The purpose of this study is to evaluate the safety and efficacy of a 28-day course of
      vancomycin for inhalation, 250 mg twice a day, (in combination with oral antibiotics) in
      eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA
      infection. Subjects will be assigned in a 1:1 ratio to either vancomycin for inhalation (250
      mg twice a day) or taste matched placebo and will be followed for 3 additional months. In
      addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or
      doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes.
      Forty patients with persistent respiratory tract MRSA infection will be enrolled in this
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

      The primary objectives of this trial are to:

        1. Determine the efficacy of an aggressive treatment protocol in eradicating persistent
           MRSA infection in individuals with CF.

        2. Determine the safety of an aggressive treatment protocol in eradicating persistent MRSA
           infection in individuals with CF.

      Secondary Objectives

      The secondary objectives of this trial are to:

        1. Determine the efficacy of an aggressive treatment protocol in improving Forced
           Expiratory Volume (FEV)1, time to exacerbation, and quality of life in individuals with
           CF and persistent MRSA infection.

        2. Determine if there is benefit to adding nebulized vancomycin to an aggressive oral
           antibiotic treatment protocol in eradicating persistent MRSA infection in individuals
           with CF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">December 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture</measure>
    <time_frame>Day 58 (Visit 5), approximately 1 month after completion of the MRSA treatment protocol</time_frame>
    <description>The hypothesis for our primary outcome is that the aggressive treatment arm will result in significantly greater eradication of persistent MRSA from the respiratory tract of CF adolescents and adults on day 58 (1 month after completion of therapy) compared to the placebo/standard treatment arm. Our primary outcome will be comparing the proportion of CF patients in the treatment arm who have a negative induced sputum MRSA culture at Day 58 to the proportion of patients in the placebo arm who have a negative induced sputum MRSA culture at Day 58.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture</measure>
    <time_frame>Day 29</time_frame>
    <description>Percentage of patients MRSA free by induced sputum respiratory tract culture one day after completion of four-week eradication protocol (Day 29) in intervention arm vs standard treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58</measure>
    <time_frame>Baseline, Day 58</time_frame>
    <description>Change in Forced Expiratory Volume (FEV1)% predicted from baseline to day number 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First CF Exacerbation</measure>
    <time_frame>Day 1 to Day 118</time_frame>
    <description>Time to First CF Exacerbation using a standardized exacerbation definition from Day 1 to Day 118</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Pulmonary Exacerbations</measure>
    <time_frame>Days 58 and 118</time_frame>
    <description>Total Number of Pulmonary Exacerbations using a standardized exacerbation definition at Days 58 and Days 118 in treatment vs. standard care group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change if FEV1% Predicted From Screening</measure>
    <time_frame>Days 29, 58, and 118</time_frame>
    <description>Change in FEV1% predicted from Screening at Days 29, 58, and 118 in treatment vs. standard care group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)</measure>
    <time_frame>Days 29 and 58</time_frame>
    <description>Change in Patient Reported Quality of Life (CFQ-R)(respiratory) from baseline to Days 29 and 58. CFQ-R stands for Cystic Fibrosis Quality of Life Measure, Respiratory Domain. Overall range of absolute score 0 to +80. Higher score means better quality of life. Positive change in score means improvement in quality of life. Minimally clinically significant difference: +/- 4.0 units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Antibiotic Resistance</measure>
    <time_frame>Day 58 (Visit 5)</time_frame>
    <description>Number of patients with newly developed MRSA resistance to vancomycin, TMP/SMX, doxycycline, or rifampin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Anti-MRSA Antibiotics (After Treatment Period)</measure>
    <time_frame>Completion of Study Drug to Day 118</time_frame>
    <description>Time between completion of Study Drug and need for anti-MRSA antibiotics to control or treat symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Vancomycin</intervention_name>
    <description>On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.</description>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <other_name>Vanc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Sterile Water)</intervention_name>
    <description>On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.</description>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Oral Rifampin by mouth for 28 days
&gt;45 kg: 600 mg by mouth daily
35-45 kg : 450 mg by mouth daily
25-34.9 kg: 300 mg by mouth daily</description>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <other_name>Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/Sulfamethoxazole (TMP/SMX)</intervention_name>
    <description>Oral trimethoprim/sulfamethoxazole (DS-160/800)
&gt;45 kg: two DS tablets twice a day by mouth (320/1600)
25-45 kg: one DS tablet twice a day by mouth (160/800)</description>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <other_name>Bactrim</other_name>
    <other_name>Septra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline
&gt;45 kg: 100 mg by mouth twice a day
35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day</description>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <other_name>Vibramycin</other_name>
    <other_name>Adoxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin Intranasal Creme</intervention_name>
    <description>Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.</description>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <other_name>Bactroban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% chlorhexidine gluconate liquid skin cleanser</intervention_name>
    <description>Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.</description>
    <arm_group_label>Inhaled Placebo and Oral Abx</arm_group_label>
    <arm_group_label>Inhaled Vanc and Oral Abx</arm_group_label>
    <other_name>Hibiclens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 12 years of age.

          2. Confirmed diagnosis of CF based on the following criteria:

             positive sweat chloride &gt; 60 mEq/liter (by pilocarpine iontophoresis) and/or a
             genotype with two identifiable mutations consistent with CF or abnormal Nasal
             Potential Difference (NPD), and one or more clinical features consistent with the CF
             phenotype.

          3. Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative and ability for subject to comply with the requirements
             of the study.

          4. Two positive MRSA respiratory cultures in the last two years at least six months
             apart, plus a positive MRSA respiratory culture at Screening Visit and Run-in (Day
             -14) Visit.

          5. At least 50% of respiratory cultures from the time of the first MRSA culture (in the
             last two years) have been positive for MRSA.

          6. Forced Expiratory Volume (FEV)1 &gt; 40% of predicted normal for age, gender, and height
             at Screening, for subjects 18 years of age or older..

          7. FEV1&gt; 60% of predicted normal for age, gender, and height at Screening, for subjects
             12--17 years of old.

          8. Females of childbearing potential must agree to practice one highly effective method
             of birth control, including abstinence. Note: highly effective methods of birth
             control are those, alone or in combination, that result in a failure rate less than 1%
             per year when used consistently and correctly. Female patients who utilize hormonal
             contraceptives as a birth control method must have used the same method for at least 3
             months before study dosing. If the patient is using a hormonal form of contraception,
             patients will be required to also use barrier contraceptives as rifampin can affect
             the reliability of hormone therapy. Barrier contraceptives such as male condom or
             diaphragm are acceptable if used in combination with spermicides

        Exclusion Criteria:

          1. An acute upper or lower respiratory infection, pulmonary exacerbation, or change in
             routine therapy (including antibiotics) for pulmonary disease within 42 days of the
             Day 1 Visit (2 weeks prior to Screening visit).

          2. Individuals on chronic continuous inhaled antibiotics without interruption who are not
             willing to substitute vancomycin or placebo for their scheduled inhaled antibiotic
             during days 0-28 of the study (every other month inhaled antibiotics are acceptable)

          3. Use of oral or inhaled anti-MRSA drugs within two weeks of the Screening Visit.

          4. History of intolerance to inhaled vancomycin or inhaled albuterol.

          5. History of intolerance to rifampin or both TMP/SMX and doxycycline.

          6. Resistance to rifampin or both TMP/SMX and doxycycline at Screening.

          7. Resistance to vancomycin at Screening.

          8. Abnormal renal function, defined as creatinine clearance &lt; 50 mL/min using the
             Cockcroft-Gault equation for adults or Schwartz equation in children, at Screening.

          9. Abnormal liver function, defined as ≥ 3x upper limit of normal (ULN), of serum
             aspartate transaminase (AST) or serum alanine transaminase (ALT), or known cirrhosis.
             at the time of Screening.

         10. Serum hematology or chemistry results which in the judgment of the investigator would
             interfere with completion of the study.

         11. History of or listed for solid organ or hematological transplantation

         12. History of sputum culture with non-tuberculous Mycobacteria in the last 6 months.

         13. History of sputum culture with Burkholderia Cepacia in the last year.

         14. Planned continuous use of soft contact lenses while taking rifampin and no access to
             glasses.

         15. Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg
             prednisone a day or 20 mg prednisone every other day

         16. Administration of any investigational drug or device within 28 days of Screening or
             within 6 half-lives of the investigational drug (whichever is longer).

         17. Patients on inhaled antibiotics must have been on the same regimen for the 4 months
             prior to screening

         18. Female patients of childbearing potential who are pregnant or lactating, or plan on
             becoming pregnant

         19. Any serious or active medical or psychiatric illness, which in the opinion of the
             investigator, would interfere with patient treatment, assessment, or adherence to the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Boyle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Chmiel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cff.org/</url>
    <description>Cystic Fibrosis Foundation website</description>
  </link>
  <link>
    <url>http://www.hopkinscf.org/</url>
    <description>Johns Hopkins Cystic Fibrosis Center website</description>
  </link>
  <reference>
    <citation>Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010 Jun 16;303(23):2386-92. doi: 10.1001/jama.2010.791.</citation>
    <PMID>20551409</PMID>
  </reference>
  <reference>
    <citation>Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21. doi: 10.1164/rccm.200802-327OC. Epub 2008 Jul 31.</citation>
    <PMID>18669817</PMID>
  </reference>
  <reference>
    <citation>Jennings MT, Boyle MP, Weaver D, Callahan KA, Dasenbrook EC. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial. Trials. 2014 Jun 12;15:223. doi: 10.1186/1745-6215-15-223.</citation>
    <PMID>24925006</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <results_first_submitted>September 17, 2018</results_first_submitted>
  <results_first_submitted_qc>October 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methicillin-resistant Staphylococcus aureus</keyword>
  <keyword>Vancomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT01594827/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Persistent MRSA Eradication Protocol (PMEP) was a double-blind, randomized, placebo-controlled study performed at two CF centers (Johns Hopkins Hospital, Baltimore, MD; and University Hospitals Rainbow Babies and Children’s Hospital, Cleveland, Ohio.) The study was conducted from October 2012 through March 2017.</recruitment_details>
      <pre_assignment_details>After qualifying for and enrolling in the study based on inclusion criteria, participants were required to again demonstrate MRSA positive respiratory culture at the run-in visit (day -14) in order to be randomized to treatment arms. 39 participants were assessed for eligibility but only 29 matched inclusion criteria and were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Vancomycin and Oral Antibiotics</title>
          <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
          <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Vancomycin and Oral Antibiotics</title>
          <description>In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
          <description>In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" lower_limit="12" upper_limit="46"/>
                    <measurement group_id="B2" value="25.0" lower_limit="14" upper_limit="38"/>
                    <measurement group_id="B3" value="25.0" lower_limit="12" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MRSA positive at baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture</title>
        <description>The hypothesis for our primary outcome is that the aggressive treatment arm will result in significantly greater eradication of persistent MRSA from the respiratory tract of CF adolescents and adults on day 58 (1 month after completion of therapy) compared to the placebo/standard treatment arm. Our primary outcome will be comparing the proportion of CF patients in the treatment arm who have a negative induced sputum MRSA culture at Day 58 to the proportion of patients in the placebo arm who have a negative induced sputum MRSA culture at Day 58.</description>
        <time_frame>Day 58 (Visit 5), approximately 1 month after completion of the MRSA treatment protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture</title>
          <description>The hypothesis for our primary outcome is that the aggressive treatment arm will result in significantly greater eradication of persistent MRSA from the respiratory tract of CF adolescents and adults on day 58 (1 month after completion of therapy) compared to the placebo/standard treatment arm. Our primary outcome will be comparing the proportion of CF patients in the treatment arm who have a negative induced sputum MRSA culture at Day 58 to the proportion of patients in the placebo arm who have a negative induced sputum MRSA culture at Day 58.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture</title>
        <description>Percentage of patients MRSA free by induced sputum respiratory tract culture one day after completion of four-week eradication protocol (Day 29) in intervention arm vs standard treatment arm</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture</title>
          <description>Percentage of patients MRSA free by induced sputum respiratory tract culture one day after completion of four-week eradication protocol (Day 29) in intervention arm vs standard treatment arm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58</title>
        <description>Change in Forced Expiratory Volume (FEV1)% predicted from baseline to day number 58</description>
        <time_frame>Baseline, Day 58</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58</title>
          <description>Change in Forced Expiratory Volume (FEV1)% predicted from baseline to day number 58</description>
          <units>% predicted FEV1</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-6.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-5.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First CF Exacerbation</title>
        <description>Time to First CF Exacerbation using a standardized exacerbation definition from Day 1 to Day 118</description>
        <time_frame>Day 1 to Day 118</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First CF Exacerbation</title>
          <description>Time to First CF Exacerbation using a standardized exacerbation definition from Day 1 to Day 118</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">No exacerbations occurred in this group</measurement>
                    <measurement group_id="O2" value="68.4" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Pulmonary Exacerbations</title>
        <description>Total Number of Pulmonary Exacerbations using a standardized exacerbation definition at Days 58 and Days 118 in treatment vs. standard care group</description>
        <time_frame>Days 58 and 118</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Pulmonary Exacerbations</title>
          <description>Total Number of Pulmonary Exacerbations using a standardized exacerbation definition at Days 58 and Days 118 in treatment vs. standard care group</description>
          <units>Exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change if FEV1% Predicted From Screening</title>
        <description>Change in FEV1% predicted from Screening at Days 29, 58, and 118 in treatment vs. standard care group</description>
        <time_frame>Days 29, 58, and 118</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Change if FEV1% Predicted From Screening</title>
          <description>Change in FEV1% predicted from Screening at Days 29, 58, and 118 in treatment vs. standard care group</description>
          <units>FEV1% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.1"/>
                    <measurement group_id="O2" value="1.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="2.1"/>
                    <measurement group_id="O2" value="1.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.4"/>
                    <measurement group_id="O2" value="-0.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)</title>
        <description>Change in Patient Reported Quality of Life (CFQ-R)(respiratory) from baseline to Days 29 and 58. CFQ-R stands for Cystic Fibrosis Quality of Life Measure, Respiratory Domain. Overall range of absolute score 0 to +80. Higher score means better quality of life. Positive change in score means improvement in quality of life. Minimally clinically significant difference: +/- 4.0 units.</description>
        <time_frame>Days 29 and 58</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)</title>
          <description>Change in Patient Reported Quality of Life (CFQ-R)(respiratory) from baseline to Days 29 and 58. CFQ-R stands for Cystic Fibrosis Quality of Life Measure, Respiratory Domain. Overall range of absolute score 0 to +80. Higher score means better quality of life. Positive change in score means improvement in quality of life. Minimally clinically significant difference: +/- 4.0 units.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="4.1"/>
                    <measurement group_id="O2" value="11.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.0"/>
                    <measurement group_id="O2" value="3.2" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Antibiotic Resistance</title>
        <description>Number of patients with newly developed MRSA resistance to vancomycin, TMP/SMX, doxycycline, or rifampin.</description>
        <time_frame>Day 58 (Visit 5)</time_frame>
        <population>No resistance to doxycycline or TMP/SMX. All developed resistance was to rifampin.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Antibiotic Resistance</title>
          <description>Number of patients with newly developed MRSA resistance to vancomycin, TMP/SMX, doxycycline, or rifampin.</description>
          <population>No resistance to doxycycline or TMP/SMX. All developed resistance was to rifampin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Anti-MRSA Antibiotics (After Treatment Period)</title>
        <description>Time between completion of Study Drug and need for anti-MRSA antibiotics to control or treat symptoms</description>
        <time_frame>Completion of Study Drug to Day 118</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Vancomycin and Oral Antibiotics</title>
            <description>In the experimental arm CF participants were randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
            <description>In the active comparator arm CF participants were randomized to 28 days of inhaled sterile placebo (saline) and treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients were followed for 3 months after completion of the treatment protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Anti-MRSA Antibiotics (After Treatment Period)</title>
          <description>Time between completion of Study Drug and need for anti-MRSA antibiotics to control or treat symptoms</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">There were no exacerbations requiring treatment in this group</measurement>
                    <measurement group_id="O2" value="58" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of enrollment until 3 months after completion of treatment.</time_frame>
      <desc>Adverse events were collected at each study visit as per protocol</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Vancomycin and Oral Antibiotics</title>
          <description>In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Placebo (Sterile Water) and Oral Antibiotics</title>
          <description>In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <description>Occurred in the follow-up period not while on active treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Exacerbation</sub_title>
                <description>All events occurred in the follow-up period not while on active treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Throat Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Drop in FEV1</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increase in Sputum Production</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pulmonary Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Easy termination leading to smaller number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mark Jennings</name_or_title>
      <organization>Johns Hopkins Unviversity School of Medicine</organization>
      <phone>410-502-7044</phone>
      <email>mjenni15@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

